Covance Continues Enhancement of Lablink Web Monitoring Tool for Clinical Trial Laboratory Tests
— New release provides sponsor access to specimen management and kit expiry data; increases autonomy and flexibility in creating and scheduling reports —
Princeton, NJ, November 29, 2005 — Covance Inc. (NYSE: CVD) today announced the further extension of its LabLinkSM on-line access tool for central laboratory test data. LabLink now provides clients with access to information pertaining to the management of test specimens and the status of time-sensitive kits supplied to investigator sites. In addition, users now have increased autonomy and flexibility to create and schedule reports on the status of their clinical trial laboratory tests. The new capabilities in LabLink were added as the result of an extensive interview process with over 500 LabLink users and are a direct response to the needs communicated by those and other LabLink users. The enhancements have been operational since September 2005.
The quality and integrity of laboratory test data is paramount to biopharmaceutical sponsors and, for that reason, Covance Central Laboratory Services' clients need to know the location of specimens and kits at all times. The addition of specimen management data to LabLink now enables sponsors to track the shipment of their study test specimens into any of Covance's central laboratory locations worldwide — in Geneva, Switzerland; Indianapolis, Indiana; Singapore; or Sydney, Australia. Sponsors can review the lab test results associated with individual specimens, as well as their subsequent storage at a Covance facility, or transfer to a third-party referral laboratory.
Another area of user concern was how to manage the timely provision of visit-specific specimen collection kits to sites. Depending on the sponsor's trial protocol, these kits may contain time-sensitive items, with "use-by" expiration dates. Use of expired kits prejudices the overall trial and drives up overall cost — not to mention inconveniencing patients, who must be re-tested. LabLink now provides kit expiry information that allows sponsors to communicate with investigator sites to ensure timely use of kits, as well as proactive re-order and re-supply of valid kits.
Another important new feature has been enhanced generation and scheduling of meaningful, customized reports, which help save time and increase the efficiency and consistency of the sponsors' clinical trial teams. The new reporting capabilities allow users to save and share report criteria — defined through LabLink's ad-hoc query function — and to auto-generate reports according to predefined schedules.
LabLink is a secure web-based system that enables Covance Central Laboratory Services' biopharmaceutical clients to monitor the progress of their clinical trial laboratory tests, through on-line review and downloadable reports, providing laboratory results, investigator and patient demographic information. Launched in February 2001, the LabLink system currently has over 7,000 registered users — medical professionals, clinical research associates, project managers, study leaders and data managers — in six continents, monitoring activity on over 3,000 clinical trials.
LabLink is available worldwide to any biopharmaceutical firm using Covance Central Laboratory Services. User training and support is provided, free-of-charge, by a dedicated LabLink instructor, who is available to guide users in using the system to monitor and manage their particular clinical study. Requests for access and user training may be submitted through LabLink itself, or via the Covance web site at www.Covance.com/LabLink.
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1 billion, global operations in 18 countries, and more than 7,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through the Covance website.
Statements contained in this press release, which are not historical facts, are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss of large contracts, and other factors described in the Company's filings with the Securities and Exchange Commission.
Covance, the Covance logo and StudyTracker are registered service marks, and LabLink and "Covance Virtual Central Laboratory" are service marks of Covance in the United States and other countries.